Selinexor Alone and in Combination With JAK Inhibitors Suppresses Pro-Inflammatory Cytokine Secretion From Primary Myelofibrosis Cells Ex Vivo (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-237; Location: LEVEL 3, HALL B3; P3 | " NF-κB transcriptional activity was assessed in TNFα-stimulated UKE1 (JAK2-V617F) and ELF-153 (JAK2wt) cells treated with selinexor (250 nM) ± JAKi (100 nM; ruxolitinib, momelotinib, pacritinib). XPO1 inhibition suppresses NF-κB-regulated cytokine production in myelofibrosis PBMCs, both alone and with JAKis. These findings support selinexor plus ruxolitinib as a potential disease-modifying strategy in JAKi-naïve myelofibrosis currently under evaluation in SENTRY. Previously presented at ASH 2025."
Combination therapy • IO biomarker • Preclinical • Myelofibrosis • Oncology • CALR • IL6 • JAK2 • TLR8 • XPO1
|
|
Trinayan Kashyap MSc 1; Christopher J Walker PhD 1; Andrea Ellero PhD 1; John Mascarenhas MD 2; Raajit Rampal MD PhD 3; Pankit Vachhani MD 4; Yair Levy MD 5; Zhanet Grudeva-Popova MD,PhD,MHM 6; Pietro Taverna PhD 1
|